Sonnet BioTherapeutics (NASDAQ: SONN), a clinical-stage company developing innovative targeted biologic drugs, is reporting the pricing of its underwritten public offering; the offering consists of 13,888,888 shares of common stock or common stock equivalents, including prefunded warrants to purchase shares of common stock in lieu of shares of common stock and investor warrants to purchase up to an aggregate of 27,777,776 shares of common stock. According to the announcement, the common stock shares (or prefunded warrants in lieu thereof) are being combined and sold with one investor warrant enabling the purchase of two shares of common stock at a combined offering price of $1.08. Total gross proceeds of the offering will be approximately $15 million, before Sonnet pays typical underwriting discounts and commissions and offering expenses. The company plans to use funds from the offering for R&D, including clinical trials, as well as general corporate purposes and working capital.
To view the full press release, visit https://nnw.fm/m2Uof
About Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific, bifunctional action. Known as FHAB (fully human albumin binding), the technology utilizes a fully human single chain antibody fragment (“scFv”) that binds to and “hitch hikes” on human serum albumin (“HAS”) for transport to target tissues. Sonnet’s FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. FHAB is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies and vaccines. For more information about the company, visit www.SonnetBio.com
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
[email protected]
NetworkNewsWire is part of the InvestorBrandNetwork.
